Together with Group 3, metastatic and Group 3 MYC amplified medulloblastoma, SHH, TP53 mutant medulloblastoma has been identified as the highest risk category with very poor prognosis, as evident from 5-year overall survival rates of only 41%8,36. The gene discussed is MYC; the disease is medulloblastoma.